1. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Issue 3 (March 2019) Authors: Bolaños-Meade, Javier; Reshef, Ran; Fraser, Raphael; Fei, Mingwei; Abhyankar, Sunil; Al-Kadhimi, Zaid; Alousi, Amin M; Antin, Joseph H; Arai, Sally; Bickett, Kate; Chen, Yi-Bin; Damon, Lloyd E; Efebera, Yvonne A; Geller, Nancy L; Giralt, Sergio A; Hari, Parameswaran; Holtan, Shernan G; Horowitz, ... Journal: Lancet Issue: Volume 6:Issue 3(2019) Page Start: e132 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗